Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer

Tímea Tőkés, A. Tőkés, Gyöngyvér Szentmártoni, Gergő Kiszner, Lilla Madaras, J. Kulka, T. Krenács, Magdolna Dank

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We aimed to analyze to what extent expression of four cell cycle regulation markers—minichromosome maintenance protein (MCM2), Ki-67, cyclin A, and phosphohistone-H3 (PHH3)—predict response to primary systemic therapy in terms of pathological complete remission (pCR). In search of an accurate and reproducible scoring method, we compared computer-assisted (CA) and routine visual assessment (VA) of immunoreactivity. We included 57 patients with breast cancer in the study. The cell cycle markers were detected using immunohistochemistry on pre-therapy core biopsy samples. Parallel CA (validated by manual labeling) and standard VA were performed and compared for diagnostic agreement and predictive value for pCR. CA and VA results were dichotomized based on receiver operating characteristic analysis defined optimal cut-off values. “High” was defined by staining scores above the optimal cut-off, while “low” had staining scores below the optimal cut-off. The CA method resulted in significantly lower values for Ki-67 and MCM2 compared to VA (mean difference, −3.939 and −4.323). Diagnostic agreement was highest for cyclin A and PHH3 (−0.586 and −0.666, respectively). Regardless of the method (CA/VA) used, all tested markers were predictive of pCR. Optimal cut-off-based dichotomization improved diagnostic agreement between the CA and VA methods for every marker, in particular for MCM2 (κ = 1, p <0.000). Cyclin A displayed excellent agreement (κ = 0.925; p <0.000), while Ki-67 and PHH3 showed good agreement (κ = 0.789, p <0.000 and κ = 0.794, p <0.000, respectively). We found all cell cycle markers (Ki-67, MCM2, cyclin A, and PHH3) predictive of pCR. Diagnostic agreement between CA and VA was better at lower staining scores but improved after optimal cut-off-based dichotomization.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalVirchows Archiv
DOIs
Publication statusAccepted/In press - Mar 30 2016

Fingerprint

Cell Cycle
Cyclin A
Breast Neoplasms
Staining and Labeling
Therapeutics
ROC Curve
Research Design
Immunohistochemistry
Maintenance
Biopsy
Proteins

Keywords

  • Breast cancer
  • Cell cycle
  • Digital pathology
  • Primary systemic therapy
  • Proliferation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer. / Tőkés, Tímea; Tőkés, A.; Szentmártoni, Gyöngyvér; Kiszner, Gergő; Madaras, Lilla; Kulka, J.; Krenács, T.; Dank, Magdolna.

In: Virchows Archiv, 30.03.2016, p. 1-12.

Research output: Contribution to journalArticle

Tőkés, Tímea ; Tőkés, A. ; Szentmártoni, Gyöngyvér ; Kiszner, Gergő ; Madaras, Lilla ; Kulka, J. ; Krenács, T. ; Dank, Magdolna. / Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer. In: Virchows Archiv. 2016 ; pp. 1-12.
@article{915f0703ed2b4c369ff8eb492124bb9d,
title = "Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer",
abstract = "We aimed to analyze to what extent expression of four cell cycle regulation markers—minichromosome maintenance protein (MCM2), Ki-67, cyclin A, and phosphohistone-H3 (PHH3)—predict response to primary systemic therapy in terms of pathological complete remission (pCR). In search of an accurate and reproducible scoring method, we compared computer-assisted (CA) and routine visual assessment (VA) of immunoreactivity. We included 57 patients with breast cancer in the study. The cell cycle markers were detected using immunohistochemistry on pre-therapy core biopsy samples. Parallel CA (validated by manual labeling) and standard VA were performed and compared for diagnostic agreement and predictive value for pCR. CA and VA results were dichotomized based on receiver operating characteristic analysis defined optimal cut-off values. “High” was defined by staining scores above the optimal cut-off, while “low” had staining scores below the optimal cut-off. The CA method resulted in significantly lower values for Ki-67 and MCM2 compared to VA (mean difference, −3.939 and −4.323). Diagnostic agreement was highest for cyclin A and PHH3 (−0.586 and −0.666, respectively). Regardless of the method (CA/VA) used, all tested markers were predictive of pCR. Optimal cut-off-based dichotomization improved diagnostic agreement between the CA and VA methods for every marker, in particular for MCM2 (κ = 1, p <0.000). Cyclin A displayed excellent agreement (κ = 0.925; p <0.000), while Ki-67 and PHH3 showed good agreement (κ = 0.789, p <0.000 and κ = 0.794, p <0.000, respectively). We found all cell cycle markers (Ki-67, MCM2, cyclin A, and PHH3) predictive of pCR. Diagnostic agreement between CA and VA was better at lower staining scores but improved after optimal cut-off-based dichotomization.",
keywords = "Breast cancer, Cell cycle, Digital pathology, Primary systemic therapy, Proliferation",
author = "T{\'i}mea Tők{\'e}s and A. Tők{\'e}s and Gy{\"o}ngyv{\'e}r Szentm{\'a}rtoni and Gergő Kiszner and Lilla Madaras and J. Kulka and T. Kren{\'a}cs and Magdolna Dank",
year = "2016",
month = "3",
day = "30",
doi = "10.1007/s00428-016-1925-x",
language = "English",
pages = "1--12",
journal = "Virchows Archiv - A Pathological Anatomy and Histopathology",
issn = "0945-6317",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer

AU - Tőkés, Tímea

AU - Tőkés, A.

AU - Szentmártoni, Gyöngyvér

AU - Kiszner, Gergő

AU - Madaras, Lilla

AU - Kulka, J.

AU - Krenács, T.

AU - Dank, Magdolna

PY - 2016/3/30

Y1 - 2016/3/30

N2 - We aimed to analyze to what extent expression of four cell cycle regulation markers—minichromosome maintenance protein (MCM2), Ki-67, cyclin A, and phosphohistone-H3 (PHH3)—predict response to primary systemic therapy in terms of pathological complete remission (pCR). In search of an accurate and reproducible scoring method, we compared computer-assisted (CA) and routine visual assessment (VA) of immunoreactivity. We included 57 patients with breast cancer in the study. The cell cycle markers were detected using immunohistochemistry on pre-therapy core biopsy samples. Parallel CA (validated by manual labeling) and standard VA were performed and compared for diagnostic agreement and predictive value for pCR. CA and VA results were dichotomized based on receiver operating characteristic analysis defined optimal cut-off values. “High” was defined by staining scores above the optimal cut-off, while “low” had staining scores below the optimal cut-off. The CA method resulted in significantly lower values for Ki-67 and MCM2 compared to VA (mean difference, −3.939 and −4.323). Diagnostic agreement was highest for cyclin A and PHH3 (−0.586 and −0.666, respectively). Regardless of the method (CA/VA) used, all tested markers were predictive of pCR. Optimal cut-off-based dichotomization improved diagnostic agreement between the CA and VA methods for every marker, in particular for MCM2 (κ = 1, p <0.000). Cyclin A displayed excellent agreement (κ = 0.925; p <0.000), while Ki-67 and PHH3 showed good agreement (κ = 0.789, p <0.000 and κ = 0.794, p <0.000, respectively). We found all cell cycle markers (Ki-67, MCM2, cyclin A, and PHH3) predictive of pCR. Diagnostic agreement between CA and VA was better at lower staining scores but improved after optimal cut-off-based dichotomization.

AB - We aimed to analyze to what extent expression of four cell cycle regulation markers—minichromosome maintenance protein (MCM2), Ki-67, cyclin A, and phosphohistone-H3 (PHH3)—predict response to primary systemic therapy in terms of pathological complete remission (pCR). In search of an accurate and reproducible scoring method, we compared computer-assisted (CA) and routine visual assessment (VA) of immunoreactivity. We included 57 patients with breast cancer in the study. The cell cycle markers were detected using immunohistochemistry on pre-therapy core biopsy samples. Parallel CA (validated by manual labeling) and standard VA were performed and compared for diagnostic agreement and predictive value for pCR. CA and VA results were dichotomized based on receiver operating characteristic analysis defined optimal cut-off values. “High” was defined by staining scores above the optimal cut-off, while “low” had staining scores below the optimal cut-off. The CA method resulted in significantly lower values for Ki-67 and MCM2 compared to VA (mean difference, −3.939 and −4.323). Diagnostic agreement was highest for cyclin A and PHH3 (−0.586 and −0.666, respectively). Regardless of the method (CA/VA) used, all tested markers were predictive of pCR. Optimal cut-off-based dichotomization improved diagnostic agreement between the CA and VA methods for every marker, in particular for MCM2 (κ = 1, p <0.000). Cyclin A displayed excellent agreement (κ = 0.925; p <0.000), while Ki-67 and PHH3 showed good agreement (κ = 0.789, p <0.000 and κ = 0.794, p <0.000, respectively). We found all cell cycle markers (Ki-67, MCM2, cyclin A, and PHH3) predictive of pCR. Diagnostic agreement between CA and VA was better at lower staining scores but improved after optimal cut-off-based dichotomization.

KW - Breast cancer

KW - Cell cycle

KW - Digital pathology

KW - Primary systemic therapy

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=84962207918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962207918&partnerID=8YFLogxK

U2 - 10.1007/s00428-016-1925-x

DO - 10.1007/s00428-016-1925-x

M3 - Article

C2 - 27026269

AN - SCOPUS:84962207918

SP - 1

EP - 12

JO - Virchows Archiv - A Pathological Anatomy and Histopathology

JF - Virchows Archiv - A Pathological Anatomy and Histopathology

SN - 0945-6317

ER -